US health authorities announced Thursday they would carry out a clinical
trial to test different dosing strategies of the Jynneos
monkeypox vaccine,
amid uncertainty over its effectiveness.
اضافة اعلان
The trial will enroll 200 adults aged 18-50 across the country, and is
sponsored by the National Institute of Allergy and Infectious Diseases.
The Jynneos vaccine, manufactured by Denmark-based Bavarian Nordic, has been
approved by the United States for the prevention of smallpox and monkeypox in
people aged 18 and older.
But while the highest-risk group, men who have sex with men, are encouraged
to get the vaccine, there is no clear picture of how well it works in real
world settings.
The new trial isn't designed to produce an efficacy estimate, but rather
measure the immune response of different dosing levels and administration
methods.
"NIAID's trial of JYNNEOS will provide important information on the
immunogenicity, safety, and tolerability of alternative dosing approaches that
would expand the current supply of vaccine," said NIAID director Anthony
Fauci in a statement.
Among the participants, one group will be injected subcutaneously -- that
is, under the skin. The vaccine is based on attenuated virus that is modified
so it can't replicate, and is given in two doses 28 days apart.
A second group will receive their shots intradermally, meaning between the
layers of the skin. This strategy is meant to expand the availability of
vaccines because it uses one-fifth of the standard dose.
A third group will also receive their shots intradermally, but at half the
dosing level of the second group.
Scientists will test the peak immune responses and compare the side effects
across the groups.
President Joe Biden's administration has bet heavily on the Jynneos vaccine
to stem the spread of monkeypox, which has affected more than 20,000 people in
the United States since May.
But the question of how well the shot prevents infection versus minimizing
disease would require further study to answer.
Historically, the virus has been spread via direct contact with lesions,
body fluids and respiratory droplets, and sometimes through indirect
contamination via surfaces such as shared bedding.
But in this outbreak, there is preliminary evidence that sexual transmission
may also play a role.
The virus causes painful skin lesions and flu-like symptoms.
Most people fully recover, but the disease can cause serious complications,
including bacterial infections, brain inflammation and death.
Read More Region & World
Jordan News
.jpg)
.jpg)
